PT2943192T - Métodos de tratamento de cancro pancreático compreendendo paclitaxel e gencitabina - Google Patents
Métodos de tratamento de cancro pancreático compreendendo paclitaxel e gencitabinaInfo
- Publication number
- PT2943192T PT2943192T PT147377915T PT14737791T PT2943192T PT 2943192 T PT2943192 T PT 2943192T PT 147377915 T PT147377915 T PT 147377915T PT 14737791 T PT14737791 T PT 14737791T PT 2943192 T PT2943192 T PT 2943192T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- pancreatic cancer
- treating pancreatic
- treating
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751820P | 2013-01-11 | 2013-01-11 | |
| US201361752355P | 2013-01-14 | 2013-01-14 | |
| US13/794,480 US9511046B2 (en) | 2013-01-11 | 2013-03-11 | Methods of treating pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2943192T true PT2943192T (pt) | 2021-07-16 |
Family
ID=51165317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147377915T PT2943192T (pt) | 2013-01-11 | 2014-01-10 | Métodos de tratamento de cancro pancreático compreendendo paclitaxel e gencitabina |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9511046B2 (OSRAM) |
| EP (1) | EP2943192B9 (OSRAM) |
| JP (3) | JP6342918B2 (OSRAM) |
| KR (1) | KR102205710B1 (OSRAM) |
| CN (2) | CN105025893A (OSRAM) |
| AU (1) | AU2013203699B2 (OSRAM) |
| BR (1) | BR112015016681A8 (OSRAM) |
| CA (1) | CA2897589C (OSRAM) |
| CY (1) | CY1124273T1 (OSRAM) |
| DK (1) | DK2943192T3 (OSRAM) |
| ES (1) | ES2878145T3 (OSRAM) |
| HK (1) | HK1216853A1 (OSRAM) |
| HR (1) | HRP20211062T1 (OSRAM) |
| HU (1) | HUE056612T2 (OSRAM) |
| IL (2) | IL239739A0 (OSRAM) |
| LT (1) | LT2943192T (OSRAM) |
| MX (1) | MX382017B (OSRAM) |
| NZ (2) | NZ630230A (OSRAM) |
| PL (1) | PL2943192T3 (OSRAM) |
| PT (1) | PT2943192T (OSRAM) |
| RS (1) | RS62076B1 (OSRAM) |
| SI (1) | SI2943192T1 (OSRAM) |
| SM (1) | SMT202100377T1 (OSRAM) |
| WO (1) | WO2014110443A1 (OSRAM) |
| ZA (1) | ZA201504877B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| PT1931321T (pt) | 2005-08-31 | 2019-05-14 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
| ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| ES2435452T3 (es) * | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
| RS59896B1 (sr) | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| KR102108959B1 (ko) | 2011-04-28 | 2020-05-11 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10751319B2 (en) | 2015-06-04 | 2020-08-25 | Crititech, Inc. | Collection device and methods for use |
| CN116473964A (zh) | 2015-06-29 | 2023-07-25 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| US10925852B2 (en) * | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| EP3439635B1 (en) | 2016-04-04 | 2020-12-09 | Crititech, Inc. | Formulations for solid tumor treatment |
| EP3595717A1 (en) * | 2017-03-17 | 2020-01-22 | Imclone, LLC | Combination therapy for pancreatic cancer |
| SG10201913649TA (en) | 2017-06-09 | 2020-03-30 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| KR102303762B1 (ko) | 2017-06-14 | 2021-09-23 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| BR112020005814A2 (pt) | 2017-10-03 | 2020-09-24 | Crititech, Inc. | administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| GB201908352D0 (en) * | 2019-06-11 | 2019-07-24 | Innovation Ulster Ltd | Sonodynamic therapy |
| US20220332832A1 (en) * | 2019-08-01 | 2022-10-20 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| US20230085602A1 (en) * | 2020-02-04 | 2023-03-16 | Swedish Orphan Biovitrum AB (publ ) | Pdac treatment regimen |
| KR20250154513A (ko) * | 2023-03-09 | 2025-10-28 | 미네암리타 테라퓨틱스, 엘엘씨 | 췌장암 치료용 약물 조합 |
| CN117099681B (zh) * | 2023-08-28 | 2024-07-05 | 南京农业大学 | 一种利用紫杉醇加倍玉米单倍体的方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| AU673057B2 (en) | 1993-02-22 | 1996-10-24 | Abraxis Bioscience, Llc | Methods for (in vivo) delivery of biologics and compositionsuseful therefor |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1023050B1 (en) | 1997-06-27 | 2013-09-25 | Abraxis BioScience, LLC | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| HK1045646A1 (zh) | 1999-05-21 | 2002-12-06 | Abraxis Bioscience, Llc | 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法 |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| KR20190034694A (ko) | 2002-12-09 | 2019-04-02 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2012201568B2 (en) | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| KR20080000682A (ko) * | 2005-04-29 | 2008-01-02 | 코산 바이오사이언시즈, 인코포레이티드 | 17-ａａｇ 또는 17-ａｇ, 또는 이들의 프로드럭을 사용한다발성 골수종의 치료 방법 |
| PT1931321T (pt) | 2005-08-31 | 2019-05-14 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
| CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| JP2007297339A (ja) * | 2006-04-29 | 2007-11-15 | Torii Yakuhin Kk | 癌を治療又は検査するための医薬 |
| EP2056812A1 (en) | 2006-08-31 | 2009-05-13 | Abraxis BioScience, LLC | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| BRPI0808635B1 (pt) | 2007-03-07 | 2022-06-07 | Abraxis Bioscience, Llc | Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| ES2435452T3 (es) | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
| WO2009126401A1 (en) | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| RU2010145529A (ru) | 2008-04-10 | 2012-05-20 | АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) | Композиции гидрофобных производных таксана и их применение |
| WO2009126934A2 (en) * | 2008-04-11 | 2009-10-15 | Seattle Genetics, Inc. | Detection and tratment of pancreatic, ovarian and other cancers |
| AU2009324464B2 (en) | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| GB0900555D0 (en) | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| WO2010105172A1 (en) | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| US20130195983A1 (en) | 2009-04-10 | 2013-08-01 | Neil P. Desai | Nanoparticle formulations and uses thereof |
| RS59896B1 (sr) | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
| JP5886191B2 (ja) * | 2009-05-28 | 2016-03-16 | アブラクシス バイオサイエンス， エルエルシー | 化学療法への反応を予測するための２つの抗ｓｐａｒｃ抗体の使用 |
| KR20120053052A (ko) | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| JP2011079788A (ja) * | 2009-10-08 | 2011-04-21 | Oita Univ | 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬 |
| AU2011204405B2 (en) * | 2010-01-05 | 2015-06-18 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| MY188911A (en) | 2010-06-02 | 2022-01-13 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| JP6031437B2 (ja) | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| KR102108959B1 (ko) | 2011-04-28 | 2020-05-11 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| HK1218506A1 (zh) | 2013-02-11 | 2017-02-24 | 阿布拉科斯生物科学有限公司 | 治療黑素瘤的方法 |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| AU2014228386B2 (en) | 2013-03-13 | 2018-11-29 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| US20170202782A1 (en) | 2014-04-06 | 2017-07-20 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| JP2018527308A (ja) | 2015-06-29 | 2018-09-20 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物のためのバイオマーカー |
| HK1247093A1 (zh) | 2015-06-29 | 2018-09-21 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| CN116473964A (zh) | 2015-06-29 | 2023-07-25 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2013
- 2013-03-11 US US13/794,480 patent/US9511046B2/en active Active
- 2013-04-11 AU AU2013203699A patent/AU2013203699B2/en active Active
-
2014
- 2014-01-10 HR HRP20211062TT patent/HRP20211062T1/hr unknown
- 2014-01-10 SM SM20210377T patent/SMT202100377T1/it unknown
- 2014-01-10 ES ES14737791T patent/ES2878145T3/es active Active
- 2014-01-10 SI SI201431853T patent/SI2943192T1/sl unknown
- 2014-01-10 LT LTEP14737791.5T patent/LT2943192T/lt unknown
- 2014-01-10 DK DK14737791.5T patent/DK2943192T3/da active
- 2014-01-10 BR BR112015016681A patent/BR112015016681A8/pt not_active Application Discontinuation
- 2014-01-10 KR KR1020157021320A patent/KR102205710B1/ko active Active
- 2014-01-10 PL PL14737791T patent/PL2943192T3/pl unknown
- 2014-01-10 EP EP14737791.5A patent/EP2943192B9/en not_active Revoked
- 2014-01-10 NZ NZ630230A patent/NZ630230A/en unknown
- 2014-01-10 RS RS20210823A patent/RS62076B1/sr unknown
- 2014-01-10 NZ NZ734971A patent/NZ734971A/en unknown
- 2014-01-10 CN CN201480013217.4A patent/CN105025893A/zh active Pending
- 2014-01-10 CA CA2897589A patent/CA2897589C/en active Active
- 2014-01-10 HU HUE14737791A patent/HUE056612T2/hu unknown
- 2014-01-10 PT PT147377915T patent/PT2943192T/pt unknown
- 2014-01-10 WO PCT/US2014/011145 patent/WO2014110443A1/en not_active Ceased
- 2014-01-10 MX MX2015008898A patent/MX382017B/es unknown
- 2014-01-10 CN CN201910067315.0A patent/CN109793728A/zh active Pending
- 2014-01-10 HK HK16104890.5A patent/HK1216853A1/zh unknown
- 2014-01-10 JP JP2015552834A patent/JP6342918B2/ja active Active
-
2015
- 2015-07-01 IL IL239739A patent/IL239739A0/en unknown
- 2015-07-07 ZA ZA2015/04877A patent/ZA201504877B/en unknown
-
2016
- 2016-10-06 US US15/287,613 patent/US9855220B2/en active Active
-
2017
- 2017-11-21 US US15/820,022 patent/US10328031B2/en active Active
-
2018
- 2018-02-21 JP JP2018028611A patent/JP6697017B2/ja active Active
-
2019
- 2019-02-27 JP JP2019033910A patent/JP2019081790A/ja active Pending
-
2020
- 2020-02-26 IL IL272905A patent/IL272905A/en unknown
-
2021
- 2021-06-30 CY CY20211100585T patent/CY1124273T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272905A (en) | Methods of treating pancreatic cancer | |
| IL288181A (en) | Cancer treatment methods | |
| IL237791A0 (en) | A method for treating cancer | |
| IL240983A0 (en) | Bladder cancer treatment methods | |
| SG11201503893RA (en) | Method of treating cancer | |
| IL240935A0 (en) | Methods of treating lung cancer | |
| EP3057594A4 (en) | Method of treating cancer | |
| EP2895206A4 (en) | METHOD FOR TREATING CARCINOMA | |
| IL240688A0 (en) | Pancreatic cancer treatment methods | |
| SG11201508878WA (en) | Methods of treating cancer | |
| IL245037A0 (en) | Treatment for pancreatic cancer | |
| EP3074040A4 (en) | Method of treating cancer | |
| HUE048625T2 (hu) | Módszer rák kezelésére | |
| ZA201507762B (en) | Methods of treating cancer | |
| GB201403083D0 (en) | Treatment of cancer | |
| AU2013904620A0 (en) | Method of treating cancer | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer |